9月22日上午，南京建邺区迎来了一场具有里程碑意义的盛会——由华检医疗（01931）主办的"全球首个RWA技术基地落成仪式"在此召开。 这座被命名为ETHK大厦（即华检医疗大厦）的建筑，不仅是华检医疗倾力打造的物理空间，更是全球现实世界资产（RWA）数字化技术研发与生态赋能的 核心基地。它的正式启用，标志着华检医疗"ETHK链上金融生态战略"迈入实体化、规模化技术落地的新纪元，也意味着南京正崛起为RWA技术的全球超级 枢纽。 一、技术落地新纪元：RWA赛道的"南京枢纽" RWA（Real World Asset）即现实世界资产代币化，正成为全球金融科技最炙手可热的领域。据香港Web3.0标准化协会报告，RWA产业正处于从概念验证向 规模化应用转型的关键节点，Defillama数据显示，截至2025年6月，RWA总锁仓量（TVL）达125亿美元，较2024年增长124%。 通过设立ETHK Inc.和ETHK HOLDINGS LIMITED两家合资公司，并计划更名为"ETHK Labs Inc."，华检医疗已经明确转型为数字产业基础设施提供者。此 次ETHK大厦的落成，是其技术战略的实体化宣言。 大厦坐落南京 ...

Group 1 - The establishment of the ETHK building marks a significant milestone for the company, representing the physical realization of its ETHK blockchain financial ecosystem strategy and positioning Nanjing as a global hub for Real World Asset (RWA) technology [1][4][14] - The RWA sector is transitioning from concept validation to large-scale application, with a projected total value locked (TVL) of $12.5 billion by June 2025, reflecting a 124% increase from 2024 [4] - The ETHK building will serve as a core base for RWA digital technology research and ecosystem empowerment, housing over 5,000 technical experts and various research facilities [7][14] Group 2 - The company has signed strategic cooperation agreements with four enterprises, including a $1.5 billion RWA tokenization deal with Chuangsheng Group, integrating six core innovative drug pipeline assets into its U.S. entity [8][13] - The partnerships aim to create a comprehensive ecosystem from biopharmaceutical innovation to legal compliance, enhancing the efficiency of asset value discovery and circulation through digitalization [13][14] - The company's "so-in-so" model aims to build a top-tier global trading ecosystem for RWA across multiple industries, providing a one-stop solution for asset digital transformation [13][14] Group 3 - The launch of the ETHK building and the strategic partnerships signify the company's transition into a scalable phase of its ETHK blockchain financial ecosystem strategy [14][15] - The RWA tokenization path chosen by the company is seen as forward-looking, with predictions estimating the global RWA market to reach $16.1 trillion by 2030, accounting for 10% of global GDP [15] - The company's "altruistic" approach allows partners to optimize their asset structures and innovate financing models, facilitating the development of cutting-edge therapies and improving patient accessibility [15][16]

Core Viewpoint - 华检医疗's stock price increased by over 16%, reaching 9.64 HKD, with a trading volume of 29.15 million HKD, following the announcement of a board meeting scheduled for August 29, 2025, to discuss mid-term performance and potential dividend payments [1] Group 1 - The company has launched several key strategic initiatives since late July, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [1] - The company is pushing its U.S. subsidiary to apply for a stablecoin license and has partnered with BGI's subsidiary to establish the world's first "Innovative Drug Intellectual Property Tokenization Fund" [1] - On August 8, the company announced the launch of a "Global Enhanced Ethereum (ETH) Treasury" strategy and completed the compliant purchase of 149 million HKD in ETH in collaboration with licensed exchange HashKey [1] Group 2 - The company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the medical innovative drug RWA trading platform ecosystem [1]

Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase, rising over 16% in the afternoon trading session, attributed to strategic initiatives and upcoming financial announcements [1] Group 1: Stock Performance - As of the latest update, Huajian Medical's stock price is reported at 9.64 HKD, with a trading volume of 29.1585 million HKD [1] Group 2: Strategic Initiatives - The company announced a board meeting scheduled for August 29, 2025, to consider and approve the mid-term performance for the six months ending June 30, 2025, and to discuss potential interim dividends [1] - Since late July, Huajian Medical has launched several key strategic initiatives, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [1] - The company is pushing its U.S. subsidiary to apply for a stablecoin license and has partnered with BGI's subsidiary to establish the world's first "Innovative Drug Intellectual Property Tokenization Fund" [1] - On August 8, Huajian Medical officially launched the "Global Enhanced Ethereum (ETH) Treasury" strategy, collaborating with the licensed exchange HashKey and completing a compliant purchase of 149 million HKD in ETH [1] - Recently, the company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the medical innovation drug RWA trading platform [1]

Group 1 - BlackRock invested over $1.2 billion in ETH, significantly outpacing its $267 million investment in BTC, indicating a shift in Wall Street's capital direction from Bitcoin as "digital gold" to Ethereum as "digital oil" [1] - The rapid growth of BlackRock's Ethereum ETF (ETHA) from $5 billion to over $10 billion in just 10 days reflects changing investor sentiment towards Ethereum [1] Group 2 - Huajian Medical announced its transformation into the first enhanced Ethereum treasury company in Hong Kong, marking a strategic advancement in the market [2] - The company initiated a global enhanced Ethereum treasury strategy with a multi-layered "downside protection" mechanism and active "yield enhancement" strategies [3] Group 3 - Huajian Medical partnered with HashKey Group to establish a compliant trading channel for large-scale ETH transactions and to explore the integration of crypto assets with real-world assets (RWA) [6] - The company approved the purchase of 5,190 ETH at an average price of HKD 28,798.21, totaling HKD 149 million, as a significant step in its treasury strategy [7] Group 4 - Wall Street's consensus indicates that Ethereum is becoming a necessary asset for institutional investment, supported by five core value pillars including its deflationary nature and yield generation capabilities [8][9] - Ethereum's role as a foundational settlement asset in the DeFi ecosystem positions it as a preferred choice for RWA tokenization and stablecoin issuance [9] Group 5 - Huajian Medical's Ethereum treasury strategy is closely linked to its core business of medical RWA tokenization, aiming to create a unique ecosystem for innovative drug assets [10] - The company's ivd.xyz exchange is designed to facilitate the issuance and trading of medical RWA, integrating Ethereum as a core asset for governance and liquidity [10] Group 6 - The treasury strategy includes an "insurance mechanism" to mitigate volatility risks and a systematic investment approach to smooth costs [13][14] - Huajian Medical aims to address the challenges in innovative drug development financing through its tokenization strategy, enhancing investment efficiency [15] Group 7 - The market is recognizing the potential for Huajian Medical's treasury model to achieve significant valuation, drawing parallels to MicroStrategy's success with Bitcoin [17] - The company's stock price surged by 118% in July and 38.43% on August 6, indicating strong market interest and potential for value discovery [19] Group 8 - Huajian Medical's strategic vision includes applying for stablecoin licenses in both Hong Kong and the U.S., aiming to connect innovative drug assets with global capital through the Ethereum ecosystem [24] - The company's ambition is to leverage Ethereum's properties to create a new benchmark in the Hong Kong market, facilitating the global circulation of Chinese biomedical assets [24]